ATLASTema Oncology ETF (CANC): outlook, holdings and fees
Tema Oncology ETF (CANC) is an exchange-traded fund and is managed by Tema ETFs. The expense ratio is 0.78% and the yield is 0.05%. The ten largest holdings are 41% of the fund.
Fund data as of Oct 14, 2026 · Price Nov 2, 2026
ATLAS view on CANC
| Last price | $41.76 (-1.3%) |
|---|---|
| ATLAS chance of a higher price in 1 month | 52% |
| Likely 1-month range (50%) | $40.13 – $43.74 |
| Normal 1-day range (±1σ) | ±1.5% |
| Distribution yield | 0.05% |
ATLAS probabilities use the same calibrated model as every stock page. A fair value is shown for companies, not funds; the holdings below link to the fair value of each company.
CANC fund facts
| Issuer | Tema ETFs |
|---|---|
| Theme | Other strategies |
| Assets under management | $205M |
| Expense ratio | 0.78% |
| Number of holdings | 50 |
| Portfolio turnover | 0% |
| Inception | Aug 14, 2023 |
| Exchange | NASDAQ |
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
CANC top holdings
| Holding | Sector | Weight |
|---|---|---|
| Revolution Medicines Inc RVMD | Healthcare | 5.06% |
| Merck & Company Inc MRK | Healthcare | 5.45% |
| Eli Lilly and Company LLY | Healthcare | 4.66% |
| Cogent Biosciences Inc UMRX | Healthcare | 4.76% |
| Novartis AG NOVN | Healthcare | 3.89% |
| Genmab AS GMAB | Healthcare | 3.70% |
| AbbVie Inc ABBV | Healthcare | 3.60% |
| BeiGene Ltd BGNE | Healthcare | 3.40% |
| Exelixis Inc EXEL | Healthcare | 3.21% |
| Halozyme Therapeutics Inc HALO | Healthcare | 3.35% |
Holdings with an ATLAS page link to their probability range, fair value and earnings calendar.
CANC sector breakdown
| Sector | Weight |
|---|---|
| Healthcare | 100.0% |
By region: North America 86.6%, Europe Developed 9.5%, United Kingdom 2.0%, Asia Emerging 2.0%.
CANC returns and risk
| Year to date | +16.6% |
|---|---|
| 1 year | +34.7% |
| 3 years (annualised) | +22.1% |
| Volatility (3 years) | 20.0% |
| Sharpe ratio (3 years) | 0.92 |
Past returns do not guarantee future results.
CANC: frequently asked questions
What does CANC invest in?
Tema Oncology ETF invests in a portfolio of securities. Its largest holdings are Revolution Medicines Inc (5.1%), Merck & Company Inc (5.5%), Eli Lilly and Company (4.7%), Cogent Biosciences Inc (4.8%), Novartis AG (3.9%).
What is the CANC expense ratio?
0.78% a year: about $78.00 for every $10,000 invested.
What is the CANC dividend yield?
0.05%. ATLAS does not hold the exact distribution dates for ETFs.
Will CANC go up?
Nobody can know. The ATLAS model puts the chance of a higher price in one month at 52%, with a likely range (50%) of $40.13 to $43.74 from $41.76 today. It is a probability, not a prediction.
How has CANC performed?
Year to date +16.6%, one year +34.7%, three years +22.1% a year. Past returns do not guarantee future results.
Similar ETFs: Other strategies
- iShares Russell 1000 ETF (IWB)
- Vanguard Extended Market ETF (VXF)
- State Street SPDR S&P MidCap 400 ETF Trust (MDY)
- iShares S&P 100 ETF (OEF)
- iShares Russell 3000 ETF (IWV)
- Vanguard Mortgage-Backed Securities ETF (VMBS)
- State Street SPDR Portfolio S&P 1500 Composite Stock Market ETF (SPTM)
- iShares Preferred and Income Securities ETF (PFF)
Educational information, not investment advice. Disclaimer